SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
---|---|---|---|---|---|---|---|---|
Jul. 02, 2021 |
Jun. 30, 2024 |
Jun. 30, 2023 |
Jun. 30, 2024 |
Jun. 30, 2023 |
Dec. 31, 2023 |
May 01, 2024 |
Jan. 17, 2019 |
|
Allowance for doubtful accounts | $ 0 | $ 0 | $ 0 | |||||
Advertising costs | 11,590 | $ 33,638 | 24,208 | $ 62,786 | ||||
Impairment of intellectual property | $ 47,980 | 0 | 0 | $ 0 | 47,980 | |||
Aging categories to estimate risk, description | The Company used the following aging categories to estimate the risk of delinquency status: (i) 0 days past due; (ii) 1-30 days past due; (iii) 31-60 days past due; (iv) 61-90 days past due; and (v) over 90 days past due | |||||||
Impairment loss | 47,980 | |||||||
Grant funding during the first year | $ 4,131,123 | $ 2,842,430 | ||||||
Grant funding | 11,029,977 | |||||||
Grant funding during the second year | 3,638,268 | 2,831,838 | ||||||
Grant funding during the third year | $ 3,260,586 | 3,453,367 | ||||||
Grant additional funding during the third year | $ 99,431 | |||||||
Grant receivables | 109,736 | $ 109,736 | 76,266 | |||||
Deferred income | 0 | 0 | ||||||
Grant income | 518,667 | 248,006 | 631,630 | 489,155 | ||||
F & A indirect costs | 0 | 0 | $ 0 | |||||
Grant funding indirect cost | 516,218 | |||||||
Research and development expenses | $ 536,362 | $ 238,419 | $ 750,196 | $ 475,806 | ||||
Ownership percentage | 50.00% | |||||||
Royalty obligations description | The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued | |||||||
Description of Non-Controlling Interest | Due to a management fee equal to 65% of the Medical Corporation’s gross collected monthly revenue, 65% of the Medical Corporation’s earnings was allocated to the Company, and 35% to the non-controlling interest | |||||||
Royalty obligations, net | $ 7,171,200 | |||||||
Minimum [Member] | ||||||||
Property plant and equipment estimated useful lives | 5 years | |||||||
Maximum [Member] | ||||||||
Property plant and equipment estimated useful lives | 15 years |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount of allowance for credit loss on receivable, classified as other and current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The amount of direct negative costs incurred in development of a direct-to-television film, as well as allocations of production overhead and capitalized interest. Examples of direct negative costs include costs of story and scenario; compensation of cast, directors, producers, extras, and miscellaneous staff; costs of set construction and operations, wardrobe, and accessories; costs of sound synchronization; rental facilities on location; and postproduction costs such as music, special effects, and editing. Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
|
X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|